Generated by AI
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a drug-development approach designed to eliminate disease-causing proteins rather than only blocking their activity. The company develops small-molecule medicines built on its proprietary TORPEDO platform, which is used to design and optimize degraders for difficult-to-treat diseases. Its current pipeline is centered on oncology, with programs aimed at cancers such as multiple myeloma, lymphoma, melanoma, colorectal cancer, and non-small cell lung cancer. C4 Therapeutics also works through strategic collaborations with other biopharmaceutical companies to expand the reach of its technology and advance new therapeutic candidates. Based in Watertown, Massachusetts, C4 Therapeutics plays a specialized role in the biotechnology market by advancing a next-generation therapeutic modality that seeks to address targets and pathways not readily handled by traditional small-molecule drugs.
Website490 Arsenal Way
Watertown, MA, 02472
United States
The latest articles about CCCC.
Here is how C4 Therapeutics, Inc. (CCCC) and CareDx (CDNA) have performed compared to their sector so far this year.
(Corrected the headline to mention no rating or price target change took place). C4 Therapeutics
Summary of Oct 20's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Summary of Apr 9's posts. Generated by AI.
Summary of Oct 16's posts. Generated by AI.
Investors talking about CCCC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.